Current therapy of cutaneous melanoma

Cutis

Volumn 63, Issue 5, 1999, Pages 293-298

  Mays, Steven R ^a   Nelson, Bruce R ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; HUMAN; MELANOMA; PATHOLOGY; PROGNOSIS; REVIEW; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERON-ALPHA; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS;

EID: 0033126406     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hall HI, Miller DR, Rogers JD, et al: Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 40: 35-42, 1999.
2. Urist MM: Management of patients with intermediate thickness melanoma. Annu Revu Med 47: 211-217, 1996.
3. Cockerell CJ: Biopsy technique for pigmented lesions. Semin Cutan Med Surg 16(2): 108-112, 1997.
4. Johnson TM, Smith JW, Nelson BR, et al: Current therapy for cutaneous melanoma. J Am Acad Dermatol 32: 689-707, 1995.
5. NIH Consensus Conference: Diagnosis and treatment of early melanoma. JAMA 268(10): 1314-1319, 1992.
6. Provost N, Marghoob AA, Kopf AW, et al: Laboratory tests and imaging studies in patients with cutaneous malignant melanomas. J Am Acad Dermatol 36: 711-720, 1997.
7. Buzaid A, Sandler A, Mani S, et al: Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11: 638, 1993.
8. Buzaid AC, Ross MI, Soong S: Classification and staging. In, Cutaneous Melanoma (Balch CM, Houghton AN, Sober AJ, et al, eds), 3rd ed, pp 37-49. Philadelphia, JB Lippincott, 1998.
9. Veronesi U, Cascinelli N: Narrow excision (1 cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg 126: 438-441, 1991.
10. Balch CM, Urist MM, Karakousis CP, et al: Efficacy of 2 cm surgical margins for intermediate thickness melanomas (1-4 mm). Ann Surg 218: 262-267, 1993.
11. Veronesi U, Cascinelli N, Adamus J, et al: Thin stage primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 318: 1159, 1998.
12. Marsden JR: Malignant melanoma excision margins. Lancet 341: 184, 1993.
13. Ross MI, Balch CM: Surgical treatment of primary melanoma. In, Cutaneous Melanoma (Balch CM, Houghton AN, Sober AJ, et al, eds), 3rd ed, pp 141-153. Philadelphia, JB Lippincott, 1998.
14. Storm FK, Mahvi DM: Treatment of primary melanoma. In, Malignant Melanoma (Lejeune FJ, Chaudhuri PK, DasGupta TK, eds), 1st ed, pp 193-204. New York, McGraw-Hill, 1994.
15. Landthaler M, Braun-Falco O, Leitl A, et al: Excisional biopsy as the first therapeutic procedure versus primary wide excision of malignant melanoma. Cancer 64: 1612, 1989.
16. Thorn M, Pouten F, Berstrome R, et al: Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 86: 761-769, 1994.
17. Dickler MN, Coit DG, Meyers ML: Adjuvant therapy of malignant melanoma. Surg Oncol Clin N Am 6(4): 793-812, 1997.
18. Barnhill RL, Mihm MC, Fitzpatrick TB: Neoplasms: malignant melanoma. In, Dermatology in General Medicine (Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds), 4th ed, pp 1078-1115. New York, McGraw-Hill, 1993.
19. Brown M: Staging and prognosis of melanoma. Semin Cutan Med Surg 16(2): 113-121, 1997.
20. Sober AJ, Day CL, Koh HK: Cutaneous melanoma in the northeastern United States: data from the Melanoma Clinical Cooperative Group. In, Cutaneous Melanoma: Clinical Management and Treatment Results (Balch CM, Milton G, eds), p 437. Philadelphia, Lippincott, 1985.
21. Sondak VK, Wofe JA: Adjuvant therapy for melanoma. Curr Opin Oncol 9: 189-204, 1997.
22. Cole BF, Gelber RD, Kirkwood JM, et al: Quality-of-life adjusted survival analysis of interferon alfa-2 B adjuvant treatment of high risk, resected cutaneous melanoma. J Clin Oncol 14: 2666-2673, 1996.
23. de Takats FG, Williams MV, Hawdins R: Adjuvant therapy for melanoma: how should we respond to high-dose interferon? Br J Cancer 77(8): 1287-1293, 1998.
24. Kirkwood JM, Strawderman MK, Ernsthoff MS, et al: Adjuvant therapy of high-risk melanoma: the role of high-dose interferon alpha 2b. In, Adjuvant therapy of Cancer VIII (Salmon SE, ed). Philadelphia, Lippincott Raven, 1997.
25. Veronesi U, Adams J, Bandiera DC, et al: Delayed regional lymph node dissection in stage I malignant melanoma of the skin of the lower extremities. Cancer 49: 2420-2430, 1982.
26. Sim FH, Taylor WF, Pritchard DJ, et al: Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 61: 697-705, 1986.
27. Balch CM, Soong S-J, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224: 255-266, 1996.
28. Reintgen DS, Crase CW, Berman C, et al: An orderly progression of melanoma nodal metastases. Ann Surg 220: 759, 1994.
29. Day CL, Mihm MC, Lew RA, et al: Cutaneous melanoma: prognostic guidelines for physicians and patients. Cancer J Clin 32: 113-122, 1982.
30. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma III. Ann Surg 193: 377-388, 1981.
31. Buzzell RA, Zitelli JA: Favorable prognosis factors in recurrent and metastatic melanoma. J Am Acad Dermatol 34: 798-803, 1996.
32. Fraker DL: Surgical issues in the management of melanoma. Curr Opin Oncol 9: 183-188, 1997.
33. Norman J, Cruse CW, Wells K, et al: A redefinition of skin lymphatic drainage by lymphoscintigraphy for malignant melanoma. Semin Surg Oncol 9: 224, 1993.
34. Koops HS, Kroon BBR, Lejeune FJ: Management of local recurrance, satellites, and in transit metastases of the limbs with isolated perfusion. In, Malignant Melanoma (Lejeune FJ, Chaudhuri PK, DasGupta TK, eds), 1st ed, 221-231. New York, McGraw-Hill, 1994.
35. Hafstrom L, Rudenstam CM, Blomquist E, et al: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant of the extremities. J Clin Oncol 9: 2091-2094, 1991.
36. Barth A, Wanek LA, Maorton DL: Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181: 193-201, 1995.
37. Allen-Mersh TG: Surgical Oncology, 1st ed, p 395. London, Chapman and Hall Medical, 1985.
38. Balch CM, Soong S, Murad TM, et al: A multifactorial analysis of melanoma IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 3: 1-126, 1998.
39. Balch CM, Soong S, Shaw HM, et al: An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In, Cutaneous Melanoma (Balch CM, Houghton AN, Milton GW, et al, eds), 2nd ed, pp 439-467. Philadelphia, JB Lippincott, 1992.
40. Karakousis CP, Velez A, Driscoll DL, et al: Metastatecotomy in malignant melanoma. Surgery 115: 295, 1994.
41. Meyers ML, Balch CM: Diagnosis and treatment of metastatic melanoma. In, Cutaneous Melanoma (Balch CM, Houghton AN, Sober AJ, et al, eds), 3rd ed, pp 325-372. Philadelphia, JB Lippincott, 1998.
42. Buzaid AC, Bedikian A, Houghton AN: Systemic chemotherapy and biochemotherapy. In, Cutaneous Melanoma (Balch CM, Houghton AN, Sober AJ, et al, eds), 3rd ed, pp 405-418. Philadelphia, JB Lippincott, 1998.
43. Atkins MB: The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 9: 205-213, 1997.
44. Chapman PB, Parkinson DR, Kirkwood JM: Biologic therapy. In, Cutaneous Melanoma (Balch CM, Houghton AN, Sober AJ, et al, eds), 3rd ed, pp 419-436. Philadelphia, JB Lippincott, 1998.
45. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 238 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907, 1994.
46. Legha SS, Ring S, Eton O, et al: Development and results of biochemotherapy in metastatic melanoma; the University of Texas MD Anderson Cancer Center experience. Cancer J Sci Am 1(Suppl): s9-s15, 1997.
47. Rogers GS, Voseburg E, Wazer D: New approaches to treating advanced melanoma. Semin Cutan Med Surg 16(2): 165-173, 1997.
48. Ruark DA, Shaw HM, Inguar C, et al: Who detects the first recurrence in stage I cutaneous malignant melanoma: patient or doctor? Melanoma Res 3 (Suppl 1): 44, 1993.
49. Weiss M, Loprinzi CL, Greagan ET, et al: Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. JAMA 274: 1703, 1995.
50. Slingluff CL, Dodge RK, Stanley WE, et al: The annual risk of melanoma progression. Cancer 70: 1917, 1992.
51. Mackie RM: Pregnancy and exogenous female sex hormones in melanoma patients. In, Cutaneous Melanoma (Balch CM, Houghton AN, Sober AJ, et al, eds), 3rd ed, pp 187-193. Philadelphia, JB Lippincott, 1998.
52. Kushvinoff BW, Kurtz C, Coit DG: Computed tomography in the evaluation of patients with Stage III melanoma. Ann Surg Oncol 4(3): 252-258, 1997.